Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 11248
Date Received: 02/03/2026
Summary:
In your Health Board area, do you have any inpatient Mental Health Wards where there is no on site Resident Doctor medical cover during the Out of Hours period? If so, what provision do you make if there is a medical emergency/urgent situation?
Date of Response: 16/04/2026
View Response: 11248.pdf
Freedom of Information Request Reference: 11309
Date Received: 18/03/2026
Summary:
Number of clinical biochemistry tests per below years, please: 2018-2019; 2019-2020; 2020-2021; 2021-2022; 2022-2023; 2023-2024
Date of Response: 15/04/2026
View Response: 11309.pdf
Freedom of Information Request Reference: 11302
Date Received: 16/03/2026
Summary:
i. The name of each ward. i.e. Ward 2 ii. The location of each ward. i.e. St John's Hospital iii. The speciality of each ward. i.e. Cardiology iv. The number of beds on each ward.
Date of Response: 15/04/2026
View Response: 11302.pdf
Freedom of Information Request Reference: 11301
Date Received: 16/03/2026
Summary:
1. Policies and Procedures Please provide copies of any current NHS Lothian policies, procedures, guidance documents, or frameworks that relate to: • communication related reasonable adjustments for patients, and • the assessment, approval, and implementation of such adjustments. 2. Application and Assessment Process Please provide any documents that describe: • how patients can request communication related reasonable adjustments, including people disadvantaged by, or unable to apply by phone. • how such requests are assessed, • who is responsible for making decisions, and • any criteria used in decision making. 3. Governance and Oversight Please provide documents that outline: • the governance structure for communication related reasonable adjustments, • any committees, roles, or teams responsible for oversight, and • how compliance with the Equality Act 2010 is monitored in relation to communication accessibility. 4. Internal Guidance to Staff Please provide any internal staff guidance, training materials, or operational instructions relating to: • communicating with patients who require written or alternative communication formats, and • handling requests for non telephone communication routes.
Date of Response: 15/04/2026
View Response: 11301.pdf
Freedom of Information Request Reference: 11275
Date Received: 09/03/2026
Summary:
I wish to make a Freedom of Information Request for the amount spent on locum/agency Dentists for the financial year of 2020, 2021, 2022, 2023, 2024 & 2025 to the present date.
Date of Response: 15/04/2026
View Response: 11275.pdf
Freedom of Information Request Reference: 11252
Date Received: 03/03/2026
Summary:
On how many occasions did staff employed by your health board report concerns relating to staffing levels or shortages in a) 23-24 b) 24-25 c) 25-26 to date.
Date of Response: 14/04/2026
View Response: 11252.pdf
Freedom of Information Request Reference: 11234
Date Received: 26/02/2026
Summary:
I am requesting aggregated data only for analysis regarding staff within your Health Board who are currently under formal Employee Relations (ER) investigation but have not been suspended from work. 1. Scope and Definitions Please include: •Staff under formal ER investigation who remain in employment and are not recorded as precautionary suspension or exclusion. •Staff placed outwith their substantive role, including: ▪ Neutral acts ▪ Temporary alternative duties ▪ Holding posts Please exclude: •Sickness absence •Organisational change redeployment not linked to a formal ER investigation Staff Groups: •Registered staff (e.g. Nursing, AHP, Medical) •Non-Registered staff (e.g. Administrative, Estates/Facilities) 2. Timeframe Please provide data for: •Current active cases •Cases opened and/or closed within the last 24 months 3. Outputs Requested A. Counts Please provide: •Total number of registered staff under formal investigation (not suspended) and moved to alternative duties. •Total number of non-registered staff under formal investigation (not suspended) and moved to alternative duties. B. Placement Status •Number of staff placed outwith their substantive role while under investigation. C. Duration •Length of time investigations have been ongoing (please provide median and range). •Length of time staff have been out of their substantive role (median and range). D. Reason Codes •Aggregate reason categories (e.g. conduct, capability).
Date of Response: 15/04/2026
View Response: 11234.pdf
Freedom of Information Request Reference: 11231
Date Received: 25/02/2026
Summary:
I would like to request a review for the FOI request I put in on ~~~~~. The due date has passed.
Date of Response: 15/04/2026
View Response: 11231.pdf
Freedom of Information Request Reference: 11228
Date Received: 25/02/2026
Summary:
Does your organisation outsource any finance and accounting (F&A) services (e.g. Accounts payable and receivable). If yes, please provide: • The name of the outsourced service provider • The name of the outsourced platform (e.g. Oracle ERP) • The contract duration (in years) • The contract end date
Date of Response: 15/04/2026
View Response: 11228.pdf
Freedom of Information Request Reference: 11218
Date Received: 24/02/2026
Summary:
I would like to request the following information. For the purposes of this request, I would prefer the data on physical discipline, where recorded, to be broken down into: a) Common assault; and b) Light smacking (actions that would previously have been regarded as reasonable punishment prior to the Children (Equal Protection from Assault) (Scotland) Act 2019). 1. Please can you provide me with copies of your organisation’s guidance on dealing with complaints relating to the Children (Equal Protection from Assault) (Scotland) Act 2019? 2. Please can you provide me with the number of reports your organisation referred 5 years prior to the implementation of the Equal Protection Act, and after its implementation, relating to physical discipline from staff members? 3. Please can you send copies of all internal emails from your communications/PR department to the senior management team relating to how to handle inquiries into cases involving physical discipline? 4. Please can you provide me with a copy of all correspondence with the Scottish Government relating to requests for data/evidence relating to physical discipline over the last 7 years? 5. Please can you provide me with data on the amount of time and money spent on training within your organisation over the last 7 years relating to the introduction of the Equal Protection Act? 6. In how many cases has your organisation provided “proportionate co-ordinated support” to families where concerns relating to physical discipline of a child have been raised over the last 5 years, in line with the National Guidance for Child Protection in Scotland 2021 (updated 2023)? 7. How does your organisation provide “proportionate co-ordinated support” to families where concerns relating to physical discipline of a child have been raised over the last 5 years, in line with the National Guidance for Child Protection in Scotland 2021 (updated 2023)?
Date of Response: 15/04/2026
View Response: 11218.pdf
Freedom of Information Request Reference: 11217
Date Received: 24/02/2026
Summary:
1. How many people were ahead of me on the waiting list on the day I joined it? 2. On average, how many patients undergo the routine procedure every week? 3. As of today, or the day on which you answer my questions, or the nearest practicable date, how many people were ahead of me on the routine list?
Date of Response: 15/04/2026
View Response: 11217.pdf
Freedom of Information Request Reference: 11212
Date Received: 19/02/2026
Summary:
Please confirm whether the Category 1 (major harm) SAER (ref. ------) relating to a Gynaecological operation at St. John’s Hospital, NHS Lothian, on ------ was notified to Healthcare Improvement Scotland, and on what date.
Date of Response: 15/04/2026
View Response: 11212.pdf
Freedom of Information Request Reference: 11208
Date Received: 19/02/2026
Summary:
Since 2021, how many people have been removed from the the CAMHS waiting list in each year, including reason/ category of removal.
Date of Response: 15/04/2026
View Response: 11208.pdf
Freedom of Information Request Reference: 11191
Date Received: 18/02/2026
Summary:
I would be grateful if you could provide the following information for NHS Lothian for the most recent complete 12 month period available (or the most recent financial year if easier): 1. Total number of outpatient appointments scheduled. 2. Total number of outpatient appointments recorded as Did Not Attend (DNA). 3. Total number of outpatient appointments cancelled by patients. 4. Total number of outpatient appointments cancelled by NHS Lothian. 5. Overall outpatient DNA rate percentage. 6. Breakdown of DNA numbers and DNA rate percentage by specialty or clinical service area, where held. 7. The name of the main appointment booking or Patient Administration System used to record outpatient appointments and cancellations (for example TrakCare or equivalent).
Date of Response: 15/04/2026
View Response: 11191.pdf
Freedom of Information Request Reference: 11379
Date Received: 09/04/2026
Summary:
Request in relation to medical record.
Date of Response: 10/04/2026
View Response: 11379.pdf
Freedom of Information Request Reference: 11362
Date Received: 02/04/2026
Summary:
Please can you assist with supplying the answers to the below questions; 1. Number of shifts booked by ON Framework agency staff broken down by provider and month from January 2025 To December 31st 2025 2. Number of shifts booked by OFF Framework agency staff broken down by provider and month from January 2025 To December 31st 2025 3. Total spend on ON Framework agency staff broken down by agency and month from January 2025 To December 31st 2025 4. Total spend on OFF Framework agency staff broken down by agency and month from January 2025 To December 31st 2025
Date of Response: 08/04/2026
View Response: 11362.pdf
Freedom of Information Request Reference: 11304
Date Received: 10/03/2026
Summary:
Number of candidates interviewed for the post in question - Gender breakdown of candidates interviewed for the post in question – Male and Female Minimum score required for appointment – Maximum score available for appointment –
Date of Response: 13/04/2026
View Response: 11304.pdf
Freedom of Information Request Reference: 11303
Date Received: 16/03/2026
Summary:
The actual process with the DV to review the rent is rather exhausting . The last review took about 18 months, total shambles. So, I would be grateful if you would give me the breakdown as requested. Please confirm why you cannot give me a breakdown of the rental values
Date of Response: 13/04/2026
View Response: 11303.pdf
Freedom of Information Request Reference: 11294
Date Received: 12/03/2026
Summary:
Request in relation to personal information.
Date of Response: 10/04/2026
View Response: 11294.pdf
Freedom of Information Request Reference: 11293
Date Received: 12/03/2026
Summary:
What is the equivalent price capping under NHS Dental in Scotland? How much should a scale and polish cost in Scotland under the NHS?
Date of Response: 10/04/2026
View Response: 11293.pdf
Freedom of Information Request Reference: 11291
Date Received: 11/03/2026
Summary:
Q1. Does your Trust treat patients for head and neck cancer (Squamous cell carcinoma)? If no, which Trust do you refer patients onto for treatment? Q2. Within your trust, how many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following? • Surgery only • Radiotherapy only • Surgery + Radiotherapy • Carboplatin (only or in combination with 5-FU) • Cisplatin (only or in combination with 5-FU) • Cetuximab with/without chemotherapy • Cetuximab with radiotherapy • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Nivolumab • Docetaxel (only or in combination with 5-FU) • Fluorouracil (5FU) monotherapy • Any other chemotherapy (without radiotherapy) • Any other chemotherapy (with radiotherapy) Q3. Could you please provide the number of patients treated in the past 3 months with the following agents for metastatic head and neck cancer (squamous cell carcinoma)? • Cetuximab with/without chemotherapy • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Nivolumab • Docetaxel (only or in combination with 5-FU) • Any other chemotherapy (without radiotherapy) • Any other chemotherapy (with radiotherapy) Q4. How many patients who received Pembrolizumab for head and neck cancer (squamous cell carcinoma) in the last 3 months, received: • Treatment every 3 weeks (200mg, Q3W) • Treatment every 6 weeks (400mg, Q6W) Q5. Does your trust participate in any clinical trials for head and neck cancer? If so, please provide the trial details and number of patients who are taking part.
Date of Response: 10/04/2026
View Response: 11291.pdf
Freedom of Information Request Reference: 11288
Date Received: 11/03/2026
Summary:
I am making a request of information held by you of any complaints, maintenance and inspection records relating to the electrical charging points at East Lothian Community Hospital, Alderston Road, Haddington, EH41 3PF.
Date of Response: 10/04/2026
View Response: 11288.pdf
Freedom of Information Request Reference: 11287
Date Received: 11/03/2026
Summary:
The number individuals diagnosed with mesothelioma in NHS Lothian, by hospital, for the year 2025.
Date of Response: 10/04/2026
View Response: 11287.pdf
Freedom of Information Request Reference: 11286
Date Received: 10/03/2026
Summary:
Please provide the number of patients resident in West Lothian who are waiting over 18 weeks for a first outpatient appointment within NHS Lothian, broken down by clinical speciality (for example: orthopaedics, dermatology, general surgery, ENT, etc.). I request that this data covers the period from 1 January 2025 to the present, and is provided in a tabular format where possible. If residency-based data is not held, please instead provide the equivalent data for services delivered at St John’s Hospital, Livingston.
Date of Response: 09/04/2026
View Response: 11286.pdf
Freedom of Information Request Reference: 11285
Date Received: 10/03/2026
Summary:
Q1. How many ovarian cancer patients (any stage) have been treated in the last 3 months with: Paclitaxel in combination with a platinum-based compound Platinum-based therapy alone (cisplatin or carboplatin) Bevacizumab in combination with paclitaxel and carboplatin Olaparib Olaparib + Bevacizumab Niraparib Rucaparib Q2. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.
Date of Response: 08/04/2026
View Response: 11285.pdf
Freedom of Information Request Reference: 11284
Date Received: 10/03/2026
Summary:
Request in relation to personal information.
Date of Response: 07/04/2026
View Response: 11284.pdf
Freedom of Information Request Reference: 11283
Date Received: 10/03/2026
Summary:
Our request is in relation to the framework agreement LR3-105-2024, NHS Lothian Measured Term Minor Building Works and Maintenance Services with a Value of Under £50k Framework, and specifically Lot 1. We understand that according to the framework call-off arrangements, works up to £10,000 are allocated in ranking order, with works above £10,000 and up to £50,000 subject to a competitive quotation process between the framework contractors. On that basis, we request that you provide the following recorded information for Lot 1, for the period from 1 August 2024 to the date of your response: 1. A comprehensive list of all projects, works orders, call-offs or instructions with an estimated or awarded value exceeding £10,000 (excluding VAT), showing for each: • unique job, order or reference number • date issued • site / property • brief description of the works • estimated value and final value, where available • contractor awarded the work • whether the opportunity was competitively quoted / tendered to framework contractors, or directly awarded • where competitively quoted / tendered, the contractors invited to quote and the successful contractor • where directly awarded, the recorded justification for not using a competitive quotation process 2. The total value of all Lot 1 work awarded through the framework during the same period, broken down by contractor. 3. The total number and total value of Lot 1 projects over £10,000 that were: • competitively quoted / tendered, and • directly awarded.
Date of Response: 09/04/2026
View Response: 11283.pdf
Freedom of Information Request Reference: 11282
Date Received: 10/03/2026
Summary:
Please confirm the following regarding the Trust’s Cardiac CT and MRI waiting lists: • Which department is responsible for CT and MRI scanning – Radiology or Cardiology? • Who is the head of department/service manager/general manager for Cardiology? • Please could you confirm the below details regarding Waiting List performance?
Date of Response: 09/04/2026
View Response: 11282.pdf
Freedom of Information Request Reference: 11281
Date Received: 10/03/2026
Summary:
Does your organisation outsource its transactional procurement function? If yes, please provide: • The name of the outsourced service provider • The name of the outsourced platform or product • The contract duration (in years) • The contract end date Other procurement support Does your organisation use a third party to deliver end to end procurement services (e.g., market insight, tendering, business cases)? If yes, please name the provider. Net Zero Strategy Does your organisation work with a third party supplier on its NHS Net Zero Strategy? If yes, please provide the supplier’s name.
Date of Response: 09/04/2026
View Response: 11281.pdf
Freedom of Information Request Reference: 11279
Date Received: 10/03/2026
Summary:
I am writing to request information under the Freedom of Information Act 2000 regarding NHS Lothian’s procurement, outsourcing, and partnership arrangements relating to social care services in Edinburgh from 1st January 2022 to the present (inclusive). Specifically, I request the following: 1. A complete list of all contracts awarded by NHS Lothian for the provision, support, or management of social care services or integrated health and social care services (including, but not limited to, domiciliary care, care home placements, reablement, mental health support, and community-based support) since 1st January 2022. For each contract, please provide: a. The contractor/partner organisation’s name b. The total contract value and duration c. The procurement process used (e.g. open tender, direct award) d. The contract start and end dates 2. Copies of: a. Procurement specifications, tender documentation, and evaluation criteria for all contracts listed in item 1 b. Signed contracts and variations thereto (with commercially sensitive or personal details redacted as appropriate) 3. All internal reports, briefing papers, or board papers relating to: a. Strategic decisions on outsourcing or procurement of social care services b. Financial assessments, risk assessments, or business cases for the contracts mentioned in item 1 c. Performance or quality reviews, audits, or monitoring reports concerning these contracts 4. All minutes and agendas (redacted as necessary) of meetings at which the contracts in item 1 were discussed, considered, or approved. This includes, but is not limited to, board meetings, procurement panels, and partnership fora. 5. Copies of all correspondence (including emails, memos, and letters) between NHS Lothian and: a. Contractors awarded contracts under item 1 b. City of Edinburgh Council or other local authorities regarding partnership arrangements or integration of social care provision in relation to these contracts 6. Copies of any policy reviews or reviews of NHS Lothian policy prompted by, or relevant to, recent pressures on social care spending, including any documents evaluating the impact of budget constraints or identifying potential service reductions (January 2022–present). 7. A dataset showing annual and monthly expenditure by NHS Lothian on externally provided social care services (2022 to present), broken down by contractor and service type, where available.
Date of Response: 09/04/2026
View Response: 11279.pdf
Freedom of Information Request Reference: 11278
Date Received: 10/03/2026
Summary:
I am writing under the Freedom of Information Act 2000 to request detailed information relating to NHS Lothian's commissioning, oversight, and performance management of smoking cessation services that have been outsourced to external providers in the last five financial years (2019/20 - 2023/24). To ensure a thorough understanding, I kindly request the following: 1. A dataset listing all contracts awarded to third-party providers (e.g., private companies, charities, social enterprises) for the delivery of smoking cessation/public health tobacco control programmes, including provider name, contract value, start/end dates, and a summary of services procured. 2. Full copies (with appropriate redactions for personal and/or commercially sensitive data) of all contracts, service specifications, and monitoring requirements for these outsourced smoking cessation services. 3. All procurement documents, including Invitations to Tender, evaluation criteria, scoring matrices, and tender evaluation reports relating to the selection of providers for outsourced smoking cessation programmes in the period requested. 4. Internal reports and briefing papers evaluating the performance, outcomes, and any risks/issues identified in relation to these outsourced services. 5. Minutes and agendas from all internal meetings (including any sub-committees or oversight groups) in which the commissioning, performance, or renewal of outsourced smoking cessation services were discussed within the timeframe specified. 6. Internal correspondence (including emails, memos, and meeting notes) between NHS Lothian Public Health Department staff and senior managers, as well as with the finance, legal, and procurement teams, pertaining to the procurement and contract management of these outsourcing arrangements. 7. Copies of any correspondence between NHS Lothian and external providers/contractors regarding service delivery, performance concerns, contract variations, or financial matters. 8. Any policy reviews, audits, or impact assessments undertaken regarding the outsourcing of smoking cessation services, including any lessons learned or recommendations for improvement. 9. Financial records showing total annual expenditure by NHS Lothian on outsourced smoking cessation services for each of the past five years, and any related budgetary reports or savings analyses.
Date of Response: 09/04/2026
View Response: 11278.pdf
Freedom of Information Request Reference: 11277
Date Received: 10/03/2026
Summary:
1. All datasets or summary spreadsheets held by NHS Lothian showing annual spending (actual and forecast) on private healthcare providers, outsourced clinical services, and non-clinical external contractors for financial years 2021/22, 2022/23, and 2023/24 (to the date of this request). 2. Copies of current and recent (since 1 January 2022) contracts, procurement award documents, and tender specifications for: a. Outsourced patient treatment (e.g., elective surgery, diagnostics) b. Agency staff provision c. Non-clinical outsourcing (such as facilities, cleaning, catering, or IT) 3. Internal reports, business cases, or options appraisals from 2022 onwards that consider or recommend outsourcing or partnership with private providers specifically as a method for managing budget constraints or waiting lists. 4. The minutes and briefing papers for any NHS Lothian Board or sub-committee meetings (including Finance, Procurement, or similar committees) since 1 January 2022 where outsourcing, private provider usage, or external contractor engagement in relation to budget pressures was discussed. 5. Correspondence (including emails, memos, and attachments) between NHS Lothian executive directors or board members and private providers, agency suppliers, or Scottish Government officials since 1 January 2022, concerning: a. The procurement or continuation of outsourced contracts related to hospital, community, or public health services; b. Service delivery changes involving private sector involvement as a response to budget pressures. 6. Any policy reviews, impact assessments, or risk assessments undertaken since 1 January 2022 concerning the use of private sector providers or outsourcing in NHS Lothian’s services, particularly in response to financial constraints or transformation programmes. 7. Financial summaries or budget models presented to NHS Lothian’s senior management or board that consider the costs, savings, or anticipated benefits of external contracting or private sector partnerships over the same period.
Date of Response: 09/04/2026
View Response: 11277.pdf
Freedom of Information Request Reference: 11276
Date Received: 10/03/2026
Summary:
For this request, please provide the following data for the period of 2020 until 2025. Please provide me with the following information for each calendar year: • Any data, records, or reports relating to complications, adverse events, or hospital admissions associated with the following non-surgical cosmetic procedures: 1. Dermal filler treatments 2. Botulinum toxin (Botox) treatments 3. Skin booster treatments Where possible, please break down this data into the following categories for each calendar year: • The number of recorded complications, adverse events, or hospital presentations arising from each treatment type, by year. • A breakdown by type of complication (e.g. infection, vascular occlusion, blindness, allergic reaction, necrosis, etc.). • Whether any of these cases were identified as having originated from Healthcare Improvement Scotland (HIS) registered clinics or non-registered providers.
Date of Response: 08/04/2026
View Response: 11276.pdf
Freedom of Information Request Reference: 11272
Date Received: 09/03/2026
Summary:
The total amount spent on providing bottled waters to patients at the Western General Hospital by month or financial quarter for the period 2024-25 and 2025-26 (to the nearest full quarter.) The total amount spent on providing bottled waters to patients at Edinburgh Royal Infirmary by month or financial quarter for the period 2024-25 and 2025-26 (to the nearest full quarter.) The total amount spent providing bottled water to patients across NHS Lothian by month or financial quarter for the period 2024-25 and 2025-26 (to the nearest full quarter.)
Date of Response: 08/04/2026
View Response: 11272.pdf
Freedom of Information Request Reference: 11271
Date Received: 09/03/2026
Summary:
I note from your response that “NHS Lothian, as all Health Boards do have a relationship with IJB/HSCP’s, and we have data sharing arrangements jointly signed by all parties for our four Lothian IJB’s (including East Lothian)”. Given that NHS Lothian is a party to the arrangements, and the hospital compiles and sends lists of admissions, can you please provide copies of those arrangements and any risk assessments in relation to that information sharing?
Date of Response: 09/04/2026
View Response: 11271.pdf
Freedom of Information Request Reference: 11270
Date Received: 09/03/2026
Summary:
In terms of the GP walk-in clinic which opened in Edinburgh in February 2026: (1) How many people have attended the clinic since it first opened? (2) How many of the people noted in (1) has the clinic been able to provide assessments to? (3) How many of the people noted in (1) has the clinic been unable to assist? (4) What is the average and longest wait time for someone attending the clinic? (5) How many GPs are operating within the clinic? (6) How many nurses are working within the clinic?
Date of Response: 08/04/2026
View Response: 11270.pdf
Freedom of Information Request Reference: 11269
Date Received: 09/03/2026
Summary:
I wish to make a Freedom of Information Request for the amount spent on locum GPs in 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024 & 2025. With a breakdown of each year.
Date of Response: 08/04/2026
View Response: 11269.pdf
Freedom of Information Request Reference: 11263
Date Received: 06/03/2026
Summary:
I understand that sublingual immunotherapy is not routinely prescribed in Scotland, so I would be grateful if you could clarify whether patients who have already started treatment in England can continue it after moving to Scotland or whether cross-border referrals are possible for ongoing immunotherapy treatment.
Date of Response: 07/04/2026
View Response: 11263.pdf
Freedom of Information Request Reference: 11262
Date Received: 05/03/2026
Summary:
Please kindly provide us with the following information: The following policies/protocols/guidance/pathways information:-  Menopausal patients presenting with vaginal bleeding  Post-menopausal patients presenting with vaginal bleeding  Suspected uterine cancer  Suspected endometrial cancer
Date of Response: 10/04/2026
View Response: 11262.pdf
Freedom of Information Request Reference: 11261
Date Received: 05/03/2026
Summary:
As of 31 December 2025: 1. What is the current longest adjusted period a patient has waited for their first CAMHS appointment? 2. Of patients who have had their first appointment, what is the current longest adjusted period a patient had waited for their next appointment?
Date of Response: 10/04/2026
View Response: 11261.pdf
Freedom of Information Request Reference: 11259
Date Received: 05/03/2026
Summary:
I request the following information relating to your organisation’s procurement and use of hired modular buildings and permanent healthcare buildings (capital or revenue funded) for the period 1 January 2024 to 31 December 2025. 1. Procurement Activity a. Has your Trust procured (or attempted to procure) any of the following in the period stated? • Hired modular buildings • Purchased modular buildings • Traditional permanent buildings For each category, please confirm Yes/No. b. If Yes to any category, please provide: • A short description of the requirement • Whether the procurement completed, was abandoned, paused, or is still in progress / awaiting funding • The anticipated or actual project value (banded values acceptable: £10m) • Whether any building is currently in use 2. Procurement Route For each procurement activity identified, please state: a. Whether a framework was used (e.g., NHS SBS, NHS Commercial Solutions, CCS, Procure23, other). If yes, please specify which framework and Lot. b. If no framework was used, please confirm whether the Trust: • Ran a standalone tender • Used a competitive quotation process • Used a direct award • Used another method (please describe) c. If a procurement was abandoned or paused, please provide the reason (e.g., funding not approved, strategic change, clinical reprioritisation, no suitable bids, supplier noncompliance, planning constraints). 3. Supplier Participation and Awards a. Please list the suppliers who: • Submitted bids • Were shortlisted • Were awarded a contract b. If no contract was awarded, please explain why. 4. Internal Factors Affecting Procurement Please provide any recorded information that explains the primary reasons why your Trust: • Did not proceed with procurement, • Has delayed decisions, or • Has not required additional buildings during the period. Examples may include: • Capital funding constraints • Revenue affordability • Changing clinical models or patient flows • Estates strategy decisions • Planning or site limitations • Lack of internal capacity to progress projects (If not formally documented, please state: “No information held.”) 5. Demand Forecasting a. Has your Trust identified a future need (within the next 2 years) for: • Temporary/hired buildings • Permanent modular buildings • Permanent traditional buildings b. If yes, please provide any available summary or highlevel outline (estimates or early-stage plans acceptable). 6. DecisionMaking Timelines For any procurement process relating to buildings: a. Please provide typical or actual timelines (if recorded) for: • Internal approval • Business case approval • Procurement duration • Contract award b. If delays occurred, please provide recorded reasons.
Date of Response: 10/04/2026
View Response: 11259.pdf
Freedom of Information Request Reference: 11202
Date Received: 20/02/2026
Summary:
1. Do you carry out ADHD review appointments? 2. Are the ADHD appointments nurse led? a. If they are nurse led what Band are they on? i.e. Band 5 b. If they are not nurse led who leads them and what banding are they? 3. How often do you review ADHD patients that are routine? 4. How long are your ADHD appointments? 5. What is your DNA policy for ADHD clinic appointments?
Date of Response: 09/04/2026
View Response: 11202.pdf
Freedom of Information Request Reference: 11199
Date Received: 20/02/2026
Summary:
Please provide the recorded information held by your Board showing how many GP practices in your Board area operate an appointment access system where a patient who contacts the practice during the day is routinely unable to request/secure an appointment and is instead told to call again at (or around) 08:00 the next working day to join a telephone queue and attempt to obtain an appointment (i.e., appointment requests are deferred to a short morning window — commonly experienced by patients as the “8am scramble”). If you hold a dataset/survey/return/dashboard or other recorded list, please provide it (CSV/Excel preferred) showing, for each practice, practice name and practice code and a simple indicator (Yes / No / Unknown) for whether it operates this model (as defined above), plus the source and date of the record. If providing practice-level information would exceed the FOISA cost limit, please instead provide the aggregate count, plus the total number of practices in your Board area (denominator) and the number recorded as Unknown / not held. In addition, please provide copies of any recorded Board materials from 1 January 2020 to present that describe, analyse, monitor, or seek to improve GP appointment access models in your Board area, including any reference to: • appointment slots being released at a set morning time (e.g., 08:00), • restricted morning call windows or daily cut-off points, • patients being asked to “call back tomorrow”, • call-handling/telephony capacity or queue management, and/or • call-back systems or other measures intended to reduce repeated calling.
Date of Response: 13/04/2026
View Response: 11199.pdf
Freedom of Information Request Reference: 11267
Date Received: 06/03/2026
Summary:
Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments? Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: • Dostarlimab (Jemperli) • Dostarlimab (Jemperli) + Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Lenvatinib + Pembrolizumab (Keytruda + Lenvima) • Pembrolizumab monotherapy (Keytruda) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Durvalumab with Platinum-based Chemotherapy • Pembrolizumab with Platinum-based Chemotherapy • Any other SACT • If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for Endometrial cancer Q3. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments: • Dostarlimab (Jemperli) + Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Durvalumab with Platinum-based Chemotherapy • Pembrolizumab with Platinum-based Chemotherapy • Any other SACT • If the Trust are using Pembrolizumab subcutaneous injection, please can you provide the number of patients who received treatment with Pembrolizumab subcutaneous injection with Platinum-based Chemotherapy for first line Endometrial cancer Q4. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Date of Response: 06/04/2026
View Response: 11267.pdf
Freedom of Information Request Reference: 11266
Date Received: 06/03/2026
Summary:
Please could you provide the following information for all dental practices providing NHS dental services within the area covered by NHS Lothian: 1. The name of each dental practice providing NHS services. 2. The address of each dental practice providing NHS services. 3. A list of all dentists associated with each practice who hold an NHS list number with your Board. For each dentist, where available, please include: • Full name • NHS list number • The practice(s) with which they are associated Please include all dentists providing NHS General Dental Services, including associates, assistants, dental body corporates or practice owners who hold an NHS list number linked to the practice.
Date of Response: 25/03/2026
View Response: 11266.pdf
Freedom of Information Request Reference: 11265
Date Received: 06/03/2026
Summary:
Request in relation to medical record.
Date of Response: 02/04/2026
View Response: 11265.pdf
Freedom of Information Request Reference: 11260
Date Received: 05/03/2026
Summary:
Please state the total expenditure by the Trust on clinical insourcing services for current financial year (April 2025 – Present). • Please note, clinical insourcing is defined as the practice where external healthcare providers deliver specialised medical services or procedures within a healthcare facility's existing infrastructure to address capacity demands or reduce patient waiting lists. • For the current financial year (April 2025 – Present), please list all clinical specialties for which the Trust utilised clinical insourcing services. For each specialty, please name the insourcing provider/s used. • For the current financial year (April 2025 – Present), please confirm the method used to procure clinical insourcing services – Direct Award / Mini-Competition / Framework Tender. • For the current financial year (April 2025 – Present), please confirm the Frameworks used to procure clinical insourcing services. • As of week commencing 2nd March 2026, please confirm if the Trust has any active/live insourcing contracts in place. If yes, please specify the clinical specialty, name of supplier and planned end date for each active contract. • For each active contract due to expire within 6 months of 31st March 2026, please confirm if the Trust would be looking to extend these services via Direct Award or if a Competitive Process will be planned to take place to re-Tender for services.
Date of Response: 13/03/2026
View Response: 11260.pdf
Freedom of Information Request Reference: 11258
Date Received: 04/03/2026
Summary:
Q1. Please provide the total number of patients treated in the last 6 months for: • Polycythaemia Vera (ICD10 code D45) • Myelofibrosis (ICD10 code D47.4) • Myelofibrosis (ICD10 code D47.4) patients aged 65 and older Q2. How many patients were treated in the past 6 months (for any disease) with: • Ruxolitinib • Fedratinib • Momelotinib Q3. How many patients were treated with Ruxolitinib in the past 6 months for the following diseases? • Myelofibrosis (ICD10 code D47.4) • Polycythaemia Vera (ICD10 code D45) • Other /Unknown
Date of Response: 07/04/2026
View Response: 11258.pdf
Freedom of Information Request Reference: 11256
Date Received: 04/03/2026
Summary:
The amount spent on legal advice regarding the Supreme Court ruling on For Women Scotland v The Scottish Ministers, who provided this advice and any action taken as a result.
Date of Response: 07/04/2026
View Response: 11256.pdf
Freedom of Information Request Reference: 11254
Date Received: 03/03/2026
Summary:
Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: •Atezolizumab (Tecentriq) •Durvalumab (Imfinzi) •Nivolumab (Opdivo) •Pembrolizumab (Keytruda) •Chemotherapy •Radiotherapy •Chemotherapy AND Radiotherapy •Osimertinib Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?
Date of Response: 07/04/2026
View Response: 11254.pdf
Freedom of Information Request Reference: 11251
Date Received: 03/03/2026
Summary:
My request covers the period 1 April 2023 to the date of this request. Section A – Current System Landscape 1. The total number of GP practices within your Health Board area, broken down by clinical system provider (e.g. EMIS Web, Vision, or other named system). Section B – Migration Activity 1. The number of practices that have submitted a request to migrate to an alternative clinical system provider. 2. The number that are in progress or have completed such a migration, including which provider they migrated from and to. 3. The number that had a migration request declined, deferred, or significantly delayed, and the reasons given. Section C – Early-Stage Enquiries (only if such records are held) 1. The number of practices that have made informal or preliminary enquiries to the Health Board about the possibility of migrating to an alternative provider. Section D – Policy and Financial Information 1. Any published policies, criteria, or guidance used by the Health Board (or NHS National Services Scotland on the Health Board’s behalf) when assessing requests to change clinical system provider. A link or reference to existing documentation would suffice. 2. The approximate dates or financial years in which current GP clinical system contracts within your Health Board area are due for renewal. 3. Whether the Health Board has allocated specific budgets for GP clinical system migrations during this period, and if so, the total amount.
Date of Response: 06/04/2026
View Response: 11251.pdf
Freedom of Information Request Reference: 11249
Date Received: 03/03/2026
Summary:
Can you please advise what work EMED Group (formed by the merger of ERS Medical and E-Zec Medical) undertakes on behalf of your health board? They are currently advertising for full time Ambulance Care Assistants for work in your area and I cannot see any public tender opportunities awarded to them for work that would meet this sudden requirement. If they are undertaking work, can you please advise what procurement activities they underwent to ensure that they are offering best value and quality of service to the health board? If tendering did not take place, please can you advise why?
Date of Response: 04/03/2026
View Response: 11249.pdf
Freedom of Information Request Reference: 11245
Date Received: 02/03/2026
Summary:
I would be grateful if you could provide the following information in relation to GP practices within your territorial health board: 1. Shared Care Agreements – Autism o The total number of GP practices within your territorial health boards. o The number of GP practices currently operating under any form of shared care agreement (SCA) relating to autism. o Of those, how many shared care agreements include prescribing of medication. o A breakdown of the type of shared care provided (for example: medication prescribing, physical health monitoring, behavioural support, or other specified responsibilities). 2. Shared Care Agreements – ADHD (Private Diagnosis Context) o The total number of shared care agreements requested in relation to ADHD diagnoses made by private providers within the last five years (if available). o The number of GP practices currently operating under any form of shared care agreement (SCA) relating to ADHD. o A breakdown of the shared care provided including medication prescribing and behavioural support. o The number of those requests that were accepted. o The number and of those requests that were refused. o The proportion (percentage) of shared care requests relating to private ADHD diagnoses that were refused. o If recorded, the most common reasons for refusal. o If recorded, the number of complaints from each GP trust 3. Policy Framework o A copy of any current territorial health board policy, guidance, or position statements regarding shared care agreements for autism and/or ADHD. o Confirmation of whether GP participation in shared care agreements within your territorial health board area is mandatory, recommended, or voluntary.
Date of Response: 07/04/2026
View Response: 11245.pdf
Freedom of Information Request Reference: 11244
Date Received: 02/03/2026
Summary:
Q1. What software does your Trust currently use for its CAFM (Computer Aided Facilities Management) solution? If multiple systems are in use, please list all solutions rather than only the primary system. Q2. What is the contract expiry date for the software used? If the contract is annual or rolling, please state this. If multiple systems are in use, please provide the known expiry date (or contract term details) for each. Q3. Who is the person responsible for managing this system? Q4. What is that person’s job title?
Date of Response: 06/04/2026
View Response: 11244.pdf
Freedom of Information Request Reference: 11243
Date Received: 02/03/2026
Summary:
1. Details of how NHS Lothian monitors and evaluates compliance with its obligations under the Equality Act 2010, including the Public Sector Equality Duty, in relation to the provision of NHS-funded hair removal treatment. 2. Any documentation relating to the rationale for this approach, and any alternative mechanisms used to ensure fair and equal treatment in terms of sex-based provision of treatment. 3. Copies of any Equality Impact Assessments, policies, guidance documents, or internal reviews relating to the commissioning or provision of NHS-funded hair removal treatment within the last ten years.
Date of Response: 03/04/2026
View Response: 11243.pdf
Freedom of Information Request Reference: 11241
Date Received: 27/02/2026
Summary:
1. In the last 60 days how many times have your Trust utilised Thornbury Nursing Services for agency nurses? Please provide data from November 2025, December 2025- first week of January 2026 if possible (please use this same time frame for all questions) 2. How many shifts were filled by Nutrix or Thornbury nursing services? 3. Which wards or departments were these TNS or Nutrix requests for? (Please include Inpatient and Community services) 4. How many long-term lines of work or block bookings are currently being supplied by off framework suppliers? 5. Which wards and departments are utilising off contract agencies on lines of work or block bookings? 6. Which off Framework suppliers are currently supplying your Trust with agency nurses? By Off framework we mean any provider that is not listed under HTE/TWS or the workforce alliance framework (nursing lots).
Date of Response: 03/04/2026
View Response: 11241.pdf
Freedom of Information Request Reference: 11238
Date Received: 27/02/2026
Summary:
Under the Freedom of Information (Scotland) Act 2002, I would like to request the following information regarding haematology services within NHS Lothian: The current median and mean waiting time for: (a) routine haematology outpatient referrals (b) urgent haematology outpatient referrals The number of patients currently waiting for a first outpatient haematology appointment, broken down by waiting time bands (e.g. 0–12 weeks, 12–26 weeks, 26–52 weeks, 52+ weeks). The longest waiting time recorded for a first haematology outpatient appointment in the most recent available month. The NHS Lothian target waiting time for haematology outpatient appointments (routine and urgent).
Date of Response: 08/04/2026
View Response: 11238.pdf
Freedom of Information Request Reference: 11237
Date Received: 27/02/2026
Summary:
Under the Freedom of Information Act 2000 I want to just clarify my previous request and request the following information: The minimum, median (average) wait time and maximum wait time from GP referral to patient attendance at Rapid Access Chest Pain clinic at your hospital trust for the following periods: January 2016 - December 2016 January 2017 - December 2017 January 2018 - December 2018 January 2019 - December 2019 January 2020 - December 2020 January 2021 - December 2021 January 2022 - December 2022 January 2023 - December 2023 January 2024 - December 2024 January 2025 - December 2025 January 2026 - February 2026
Date of Response: 08/04/2026
View Response: 11237.pdf
Freedom of Information Request Reference: 11236
Date Received: 27/02/2026
Summary:
I am seeking information in relation to any local trials, pilot schemes or implementation activity within your Health Board area relating to Martha’s Rule, Call for Concern or any patient- or family-initiated escalation of care mechanism. Specifically, please provide the following information: 1) Whether your Health Board has, at any time since January 2023, undertaken, participated in, or planned: · a pilot · trial · test of change · local implementation Of a patient- or family-initiated escalation of care process (including but not limited to Martha’s Rule or Call for Concern). 2) If yes, please can you provide: · the name of the scheme or initiative · the dates it commenced and (if applicable) concluded · the clinical settings involved (e.g. acute, ward-based, specialty-specific) · whether the scheme was formal or informal. 3) Any evaluations, reports, data summaries or internal reviews produced in relation to such trials or initiatives. 4) Whether any data from such trials or initiatives was shared with: · the Scottish Government · NHS Scotland · Healthcare Improvement Scotland · any other national body. If no such trials or initiatives have taken place, please confirm this explicitly.
Date of Response: 03/04/2026
View Response: 11236.pdf
Freedom of Information Request Reference: 11232
Date Received: 26/02/2026
Summary:
If you use software for the workforce systems below - please could you provide the software provider name, contract start date, contract end date and total spend in the last year? 1. Bank (Tech) - Medics (examples: RLDatix, Patchwork Health, Locum's Nest, Agile LMS, etc.) Please provide the name of the software provider or service provider directly.
Date of Response: 06/04/2026
View Response: 11232.pdf
Freedom of Information Request Reference: 11230
Date Received: 26/02/2026
Summary:
Please provide all information held relating to the policy expressed on the East Lothian GIRFEC website about the inability of NHS Lothian to respond via email to parent/carer queries.
Date of Response: 08/04/2026
View Response: 11230.pdf
Freedom of Information Request Reference: 11229
Date Received: 26/02/2026
Summary:
For the last financial year, what was the total amount spent on translation costs? Can you provide a breakdown of these costs by language translated. Do you hire any dedicated translators? If so provide details of how many, total salary cost and for what language.
Date of Response: 06/04/2026
View Response: 11229.pdf
Freedom of Information Request Reference: 11226
Date Received: 25/02/2026
Summary:
1. In 2024-25 and 2025-26, how much has been spent by this health board on providing healthcare services to asylum seekers? This would include, but is not limited to, spending relating to vaccinations, STI checks, general healthcare assessments etc. 2. Could I also be provided with any correspondence (including emails, letters, phone calls, handwritten notes, WhatsApp messages or any other documents) between members of the health board and home office officials regarding the provision of healthcare for asylum seekers. Please provide correspondence between 1 October 2025 and 25 February 2026 inclusive.
Date of Response: 06/04/2026
View Response: 11226.pdf
Freedom of Information Request Reference: 11225
Date Received: 25/02/2026
Summary:
How many prisoners currently held within the Scottish Prison Service have a diagnosis of Acquired Brain Injury? How many of those prisoners acquired their brain injury prior to being held in prison?
Date of Response: 24/03/2026
View Response: 11225.pdf
Freedom of Information Request Reference: 11224
Date Received: 23/02/2026
Summary:
Please provide me with the following information; • The number of emergency CT Aortograms carried out each year between 1.1.16 and 31.12.25 • The number of patients with a primary or secondary ICD-10 diagnosis of I-71.0 each year between 1.1.16 and 31.12.25 with an emergency inpatient admission (Please do not include A&E discharge diagnosis). • The number of patients with a primary or secondary ICD-10 diagnosis of I-71.0 discharged dead each year between 1.1.16 and 31.12.25.
Date of Response: 07/04/2026
View Response: 11224.pdf
Freedom of Information Request Reference: 11223
Date Received: 25/02/2026
Summary:
I am writing to request the below information under the Freedom of Information Act 2000. • The number of young people (18-24 year olds inclusive) receiving mental health treatment- both community and inpatient. • The number of them who have been receiving treatment more than once (not their first time).
Date of Response: 03/04/2026
View Response: 11223.pdf
Freedom of Information Request Reference: 11222
Date Received: 25/02/2026
Summary:
Under the Freedom of Information Act please tell me how long the waiting list is for people to have neuro-psychological tests - Edinburgh only. Specifically, I am interested in the waiting time for people thought to have neurodegenerative conditions such as Alzheimer's or other dementias, What is the longest time someone on such a list has had to wait? How many people are on the list?
Date of Response: 03/04/2026
View Response: 11222.pdf
Freedom of Information Request Reference: 11221
Date Received: 25/02/2026
Summary:
I would like to request the following: 1. The Board’s current policy, guideline, protocol, RICaD, shared care agreement, formulary statement, or any other document relating to the prescribing of liothyronine (T3), whether as monotherapy or in combination with levothyroxine. 2. Any equality impact assessment (EIA) or equality related analysis carried out in relation to liothyronine prescribing or changes to liothyronine policy.
Date of Response: 03/04/2026
View Response: 11221.pdf
Freedom of Information Request Reference: 11216
Date Received: 24/02/2026
Summary:
Please provide details regarding patients with delayed discharge: 1. Of those patients who experienced delayed discharge and were discharged in (i) 2022/23, and (ii) 2023/24, how many were delayed due to health and social care reasons for (a) 1-3 months, (b) 3-6 months (c) 6-9 months, (d) 9-12 months, (e) 12-18 months, (f) 18-24 months, and (g) over 24 months. 2. What was the longest any patient discharged in (i) 2022/23, and (ii) 2023/24 was delayed due to a delayed discharge based on health and social care reasons? What proportion of this delay was attributed to each of (a) assessment, (b) funding, (c) place availability, (d) care arrangements and (e) transport? 3. Of those patients currently experiencing delayed discharge due to health and social care reasons, how many have been delayed for (a) 1-3 months, (b) 3-6 months (c) 6-9 months, (d) 9-12 months, (e) 12-18 months, (f) 18-24 months, and (g) over 24 months. 4. What is the longest any patient currently experiencing delayed discharge due to health and social care reasons has been delayed. What proportion of this delay is attributable to each of (a) assessment, (b) funding, (c) place availability, (d) care arrangements and (e) transport?
Date of Response: 03/04/2026
View Response: 11216.pdf
Freedom of Information Request Reference: 11215
Date Received: 24/02/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis or regimen, with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available? Name of medicine 1.1 Daratumumab 1.2 Lenalidomide Q2. How many patients with Multiple Myeloma were treated with the following medicines in combination, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available? Name of medicine 2.1 Daratumumab + Bortezomib + Dexamethasone [DVd] 2.2 Daratumumab + Bortezomib + Thalidomide + Dexamethasone [DVTd] 2.3 Daratumumab + Lenalidomide + Dexamethasone [DRD] 2.4 Daratumumab + Bortezomib + Lenalidomide + Dexamethasone [DVRd] 2.5 Daratumumab (monotherapy) 2.6 Lenalidomide + Dexamethasone [Rd] 2.7 Lenalidomide (maintenance monotherapy) 2.8 Belantamab mafodotin (monotherapy) 2.9 Belantamab mafodotin + Bortezomib + Dexamethasone [BVd] 2.10 Belantamab mafodotin + Pomalidomide + Dexamethasone [BPd] 2.11 Isatuximab + Bortezomib + Lenalidomide + Dexamethasone [IsaVRd] 2.12 Isatuximab + Pomalidomide + Dexamethasone [IsaPd] Q3. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available? Name of medicine 3.1 Acalabrutinib (Calquence) 3.2 Ibrutinib (Imbruvica) 3.3 Pirtobrutinib (Jaypirca) 3.4 Venetoclax (Venclyxto) 3.5 Zanubrutinib (Brukinsa) 3.6 Rituximab 3.7 Obinutuzumab (Gazyvaro) Q4. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available? Name of medicine 4.1 Acalabrutinib (Calquence) 4.2 Ibrutinib (Imbruvica) 4.3 Pirtobrutinib (Jaypirca) 4.4 Venetoclax (Venclyxto) 4.5 Zanubrutinib (Brukinsa) 4.6 Obinutuzumab (Gazyvaro) 4.7 Rituximab Q5. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available? Name of monotherapy or combination 5.1 Ibrutinib + Venetoclax 5.2 Obinutuzumab + Venetoclax 5.3 Ibrutinib monotherapy / maintenance 5.4 Venetoclax monotherapy 5.5 Venetoclax + Rituximab 5.6 Rituximab monotherapy 5.7 Rituximab + Fludarabine + Cyclophosphamide 5.8 Rituximab + R-CHOP 5.9 Rituximab + Bendamustine 5.10 Rituximab + Chlorambucil 5.11 Obinutuzumab + Chlorambucil Q6. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available? Name of monotherapy or combination 6.1 Acalabrutinib 6.2 Ibrutinib 6.3 Zanubrutinib 6.4 Ibrutinib + R-CHOP / R-DHAP 6.5 Pirtobrutinib Q7. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available? Name of medicine 7.1 Azacitidine 7.2 Cytarabine 7.3 Venetoclax (Venclyxto) Q8. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available? Name of combination 8.1 Venetoclax + Azacitidine (with or without posaconazole) 8.2 Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C) Q9. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available? Name of medicine 9.1 Fedratinib (Inrebic) 9.2 Momelotinib (Omjjara) 9.3 Ruxolitinib (Jakavi) 9.4 Hydroxycarbamide Q10. How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months between the start of October 2025 and end of December 2025, or latest 3-month period available? Name of medicine 10.1 Ruxolitinib (Jakavi) 10.2 Hydroxycarbamide
Date of Response: 24/03/2026
View Response: 11215.pdf
Freedom of Information Request Reference: 11211
Date Received: 23/02/2026
Summary:
Among all the children and young people from your health board area who waited in excess of the 18-week CAMHS standard and started their treatment in (a) 2022-23 (b) 2023-24 (c) 2024-25 and (d) 2025-26 to date (including those still waiting), what was the total number of days over the 18-week standard that they collectively waited. Please break down the figures for each year specified. For example, if a child began their treatment after 30 weeks, then that child would contribute 84 days towards the total for the year in which they started their treatment (12 weeks x 7 days).
Date of Response: 03/04/2026
View Response: 11211.pdf
Freedom of Information Request Reference: 11210
Date Received: 23/02/2026
Summary:
I would like the policy that predated the dec 25 that is title ‘NHS Lothian Supplementary staffing – operational principles’. I would like the previous policy.
Date of Response: 25/03/2026
View Response: 11210.pdf
Freedom of Information Request Reference: 11209
Date Received: 23/02/2026
Summary:
For hospitals proving neonatal or SCBU services, please could you provide the following: 1. Confirmation of whether Family Integrated Care (FICare) is currently implemented in your neonatal unit(s), and if so, the date of initial implementation. 2. Copies of any internal policies, protocols, or guidance documents relating to FICare. 3. Details of any staff training programmes or materials used to support FICare delivery. 4. Details of any staff training programmes or materials used to support FICare delivery relating to older siblings. 5. Any audit reports, evaluations, or outcome data relating to the effectiveness or impact of FICare on neonatal care or family experience. 6. If FICare is not currently implemented, please indicate whether there are plans or discussions underway to introduce it. In addition (and if relevant), please could the hospital provide information on its policies or regulations regarding parental and sibling access to babies receiving neonatal care: 1. Are both parents and siblings permitted to spend time with babies in neonatal care units? 2. Are there any time restrictions or limitations on how long parents or siblings may spend with babies in neonatal care? 3. Does the hospital have any policies or practices to ensure that babies from multiple births (e.g. twins, triplets) receive equal parental contact time compared to singleton babies?
Date of Response: 07/04/2026
View Response: 11209.pdf
Freedom of Information Request Reference: 11207
Date Received: 23/02/2026
Summary:
Please provide all form of communication between -------- and Equality Network/Scottish Trans between 2016 and 2025.
Date of Response: 03/04/2026
View Response: 11207.pdf
Freedom of Information Request Reference: 11206
Date Received: 23/02/2026
Summary:
Are medical staff allowed to obstruct a patient's legal documents of a living will requests? Are medical staff allowed to obstruct a patient's welfare attorney acting for them when the patient has incapacity? What action is taken if medical staff do so ( to both questions)?
Date of Response: 03/04/2026
View Response: 11206.pdf
Freedom of Information Request Reference: 11204
Date Received: 23/02/2026
Summary:
Can you please provide the following information: • How much in total was spent by maternity departments you are responsible for, for each calendar year dating back to 2016? Including all staffing, equipment and other costs. o The preference is for calendar years, but if the information is more easily recovered by financial years and converting to calendar years would make the request exceed the Section 12 cost limit, delivering the data by financial year would be okay. o Likewise, if it would exceed the Section 12 cost limit to extract data beyond a certain year, providing data for as many years as would not exceed the limit would be okay. • How many cycles of IVF treatment do you offer to eligible patients?
Date of Response: 07/04/2026
View Response: 11204.pdf
Freedom of Information Request Reference: 11203
Date Received: 20/02/2026
Summary:
Payroll and Pensions Outsourcing Does your organisation outsource its payroll and pensions function? If yes, please provide: • The name of the outsourced service provider • The contract duration (in years) • The contract end date Outsourced Payroll and Pension (yes/no)? Name of the outsourced service provider? Contract duration (in years)? Contract end date? Payroll and Pension Services Workforce and HR processes Does your organisation outsource any other workforce and HR processes? If yes, please confirm: • Which workforce and HR services your organisation outsources, to which supplier(s) Smartcard production and management. Does your organisation outsource smartcard production & management? If yes, please provide: • The name of the outsourced service provider If no, please confirm: • Which department is responsible for providing the service • Whether you provide this service to other organisations
Date of Response: 17/03/2026
View Response: 11203.pdf
Freedom of Information Request Reference: 11201
Date Received: 20/02/2026
Summary:
Please provide a list of the currently vacant GP posts in salaried practices in your health board area which have been advertised on more than one occasion (i.e. been re-advertised). For each post that has been advertised on more than one occasion, please provide (i) the number of times it has been advertised and (ii) each time it was advertised, how many applications were received. Please provide the longest length of time that any currently vacant GP post has been unfilled and the location of this vacancy. Please provide a position statement for each salaried GP practice in your health board area which is currently experiencing recruitment difficulties. For example, how many vacancies are there at each of these practices, how long has the recruitment process been underway and what impact has this had on the services available to patients.
Date of Response: 18/03/2026
View Response: 11201.pdf
Freedom of Information Request Reference: 11198
Date Received: 20/02/2026
Summary:
Please provide the following information for the six-month period from 1 August 2025 to 31 January 2026: 1. The Trust's total monthly expenditure on agency temporary staffing, broken down by the following staff groups: • Registered Nurses • Healthcare Assistants / Support Workers • Allied Health Professionals 2. For the total agency spend above, please confirm: • The proportion of spend via contracted/framework agencies • The proportion of spend via non-contracted or off-framework agencies 3. Please confirm whether the Trust currently utilises a Managed Service Provider (MSP) or Neutral Vendor arrangement for temporary staffing and, if so, the name of the provider.
Date of Response: 01/04/2026
View Response: 11198.pdf
Freedom of Information Request Reference: 11197
Date Received: 19/02/2026
Summary:
- Are you currently using any implanted cardiac device / pacemaker electronic database solution? If yes, what is the name of the system and / or supplier and the date of the end of the contract - Are you currently using any CVIS (Cardiovascular Information Systems) or CIS (Clinical Information System) within the Cardiology Dept, and if so, which ones? - Which of the following device manufacturers do you use for implanted cardiac devices / pacemakers? Medtronic, Abbott, Boston or Other, please specify - What is the name of your Electronic Patient Record (EPR) solution? - What is the name of your Patient Administration System (PAS) solution?
Date of Response: 17/03/2026
View Response: 11197.pdf
Freedom of Information Request Reference: 11196
Date Received: 19/02/2026
Summary:
I am writing to obtain information about the number of non-British citizens treated by your trust. Please include the following for the previous 3 financial years (2022-23, 2023-24 and 2024-25) : • The total number of non-British citizens treated in the previous 3 financial years. • The total cost of treating those patients • The total amount recovered from those patients • The total number of adults treated who did not have a NHS number in the previous 3 financial years • The total cost of treating those patients • The total amount recovered from those patients
Date of Response: 18/03/2026
View Response: 11196.pdf
Freedom of Information Request Reference: 11195
Date Received: 18/02/2026
Summary:
I am writing to make a Freedom of Information request for monthly data for 2024 and 2025, as well as overall totals, regarding ammonia testing and sample rejection for the Royal Infirmary of Edinburgh. Specifically, I am requesting: 1. Number of patients presenting to the hospital 2. Number of ammonia tests requested, broken down as follows: a. Adults in A&E b. Paediatrics in A&E c. Adults in inpatient wards (excluding A&E) d. Paediatrics in inpatient wards (excluding A&E) 3. Number of ammonia tests rejected by the laboratory
Date of Response: 08/04/2026
View Response: 11195.pdf
Freedom of Information Request Reference: 11192
Date Received: 18/02/2026
Summary:
Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage): • Cobimetinib • Dabrafenib • Dabrafenib + Trametinib • Dacarbazine • Denosumab • Encorafenib + Binimetinib • Ipilimumab monotherapy • Ipilimumab + Nivolumab • Nivolumab monotherapy • Nivolumab + Relatlimab • Pembrolizumab • Trametinib • Vemurafenib • Vemurafenib + Cobimetinib • Other active systemic anti-cancer therapy • Palliative care only Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY: • Ipilimumab monotherapy • Ipilimumab + Nivolumab • Nivolumab monotherapy • Nivolumab + Relatlimab • Pembrolizumab • Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) • Other active systemic anti-cancer therapy • Palliative care only Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma? • Ipilimumab (monotherapy) • Nivolumab (monotherapy) • Nivolumab AND Ipilimumab (combination) • Nivolumab AND Relatlimab • Pembrolizumab • Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) • Other active systemic anti-cancer therapy *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. Q4. Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.
Date of Response: 18/03/2026
View Response: 11192.pdf
Freedom of Information Request Reference: 11189
Date Received: 17/02/2026
Summary:
Please provide the following information relating specifically to the use of Kenalog (triamcinolone) within your Ophthalmology department: 1. The number of Kenalog administrations carried out in Ophthalmology for each of the last three financial years. 2. A breakdown of the clinical indications recorded for Kenalog use in Ophthalmology (e.g., uveitis, macular oedema, post operative inflammation), if available. 3. Any local guidelines, protocols, or clinical policies governing the use of Kenalog in Ophthalmology. 4. Any recorded adverse events, Datix reports, or safety concerns relating to Kenalog use in Ophthalmology during the same period. 5. The number of vials issued by pharmacy to Ophthalmology for Kenalog in each of the last three financial years, if held. 6. Whether Kenalog (triamcinolone) is listed on the Trust’s formulary for Ophthalmology, and if so, any restrictions or criteria for its use. 7. As Kenalog has been withdrawn from the UK market, please provide any recorded information, internal communications, policies, or decisions relating to: •whether the Ophthalmology department is continuing to use existing stock, •any plans or decisions to discontinue its use, and •any identified or recommended alternative treatments.
Date of Response: 17/03/2026
View Response: 11189.pdf
Freedom of Information Request Reference: 11186
Date Received: 17/02/2026
Summary:
1. Does your health board employ cancer care patient navigators/cancer pathway navigators (I am aware that this job title varies from board to board) 2. How many WTE staff are currently employed? 3. How many WTE vacancies exist? 4. Does every cancer patient get assigned a cancer care patient navigator/cancer pathway navigator?
Date of Response: 07/04/2026
View Response: 11186.pdf
Freedom of Information Request Reference: 11170
Date Received: 16/02/2026
Summary:
I would like to submit a Freedom of Information (FOI) request for the following data for NHS Lothian relating to Pompe disease for the period 1 October 2025 to 31 December 2025. For reference, Pompe disease may be coded under: · ICD-10: E74.0 (Glycogen storage disease), or more specifically noted as Acid Maltase Deficiency / Pompe disease · SNOMED CT Concept ID: 86651009 – Glycogen storage disease type II (Pompe disease) If exact matches are unavailable, please provide the nearest equivalent coding used by your Trust and specify the codes applied. Table 1 – Patients Treated and Volume used (Oct–Dec 2025) Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti) Table 2 – New Patients Treated by Product (Oct–Dec 2025) Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti) Table 3 – Segmentation of Infantile- and Late-Onset Patients treated by product (Oct–Dec 2025) Avalglucosidase(Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti) Table 4 – New Patients and switch patients by product (Oct–Dec 2025) Number of Naïve (New Start) Patients Number of Patients Switching To this product Number of Patients Switching From this Product Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti)
Date of Response: 25/03/2026
View Response: 11170.pdf
Freedom of Information Request Reference: 11169
Date Received: 11/02/2026
Summary:
Please can you provide any communication with any organisation or unit within the NHS Lothian organisation tasked with cleaning up the increased or decreased littering of cigarettes butts near the entrance doors (any). And please can you provide any communication with any organisation within the foyer area ground floor level which sells coffee. Only the site at Little France being the Royal Infirmary Edinburgh. Both sets of doors ie main entrances. And only ground floor main mall coffee area.
Date of Response: 08/04/2026
View Response: 11169.pdf
Freedom of Information Request Reference: 11165
Date Received: 13/02/2026
Summary:
1. Please provide the record from the organisation's Contract Register or equivalent procurement log entry pertaining to the current contract for the Endpoint Detection and Response (EDR) solution (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used]) 2. Please provide the following information for the current maintenance and licensing agreement for the primary Perimeter Firewall/Intrusion Prevention System (IPS) solution (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used]) 3. Please provide the following information for the service agreement covering the Cloud Security Posture Management (CSPM) platform or equivalent third-party cloud security monitoring too (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used]) 4. Please provide the following information for the service agreement covering your Identity & Access Management (IAM) software (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used]) 5. Please provide the record from the organisation's Contract Register or equivalent procurement log entry pertaining to the current contract for your current Managed Security / SOC Services (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used]) 6. Please provide the record from the organisation's Contract Register or equivalent procurement log entry pertaining to the current contract for your current Vulnerability & Compliance Management service (Include Supplier, Product Name, Start Date, Expiry Date, Annual spend 2025/2026 [£], Additional notes [including any framework used])
Date of Response: 24/03/2026
View Response: 11165.pdf
Freedom of Information Request Reference: 11160
Date Received: 11/02/2026
Summary:
Please provide the most recent available data (as of [insert current date, e.g., February 2026], or the latest reported figures if more recent data is unavailable). 1. Current waiting lists / demand for assessments: o The total number of people currently waiting for an adult (18+) ADHD assessment via NHS-commissioned services (including both local NHS pathways and Right to Choose providers). o The total number of people currently waiting for an adult (18+) autism assessment via NHS-commissioned services (including both local NHS pathways and Right to Choose providers). o If available separately: the number of people waiting specifically via Right to Choose referrals (or an estimate/indication of the proportion). o The same information as above, but for children and young people (under 18), if your ICB commissions or holds data for neurodevelopmental assessments in that age group via Right to Choose. o Median and longest reported waiting times (in weeks or months) for adult ADHD and adult autism assessments in your area (via any NHS-funded route, including Right to Choose). 2. Indicative Activity Plans (IAPs) or activity limits: o Details of any current Indicative Activity Plans (IAPs), activity caps, funding limits, or restrictions applied to Right to Choose providers for adult ADHD and/or autism assessments in the current financial year (or most recent period). o The total number of assessments (or indicative activity volume) allocated or agreed for Right to Choose providers for adult ADHD and adult autism in the current financial year. o Any planned changes to IAPs, caps, or commissioning for the next financial year. 3. Commissioning of new providers: o The name(s), job title(s), and direct email address(es) (or team inbox if individual contact is not available) of the person(s) or team responsible for commissioning / procuring new or additional providers for ADHD and/or autism assessment services under the Right to Choose framework. o Any current open procurement/framework opportunities, expressions of interest, or processes for approving new Right to Choose providers for adult ADHD and/or autism assessments. o If no such process is currently open, the anticipated timeline for the next review or commissioning round for additional providers.
Date of Response: 25/03/2026
View Response: 11160.pdf
Freedom of Information Request Reference: 11140
Date Received: 06/02/2026
Summary:
1. In each hospital in this health board, how many wards are currently mixed sex? This would encapsulate wards where biological males and females share a hospital ward. Please provide as much detail as possible, including the hospital(s) and ward(s) in question. 2. In 2025-26, has the health board been aware of any incidents in which single sex wards were occupied by both male and female patients due to operational pressures. I would define operational pressures as any incidents in which a surge in patient numbers or demand led to single sex wards being shared by both males and females.
Date of Response: 24/03/2026
View Response: 11140.pdf
Freedom of Information Request Reference: 11135
Date Received: 05/02/2026
Summary:
In addition to the national data on A&E admissions (see link below), do your hospitals collect any data on the causes of hospital admissions? (https://publichealthscotland.scot/healthcare-system/urgent-and-unscheduled-care/accident-and-emergency/downloads-and-open-data/our-downloads/) We are specifically interested in any data that records the causes of hospital admissions resulting from a breakdown in social care arrangements, or patients not coping at home, for the person cared for or their carer. If you collect such data, please provide it for the last five years. Has your health board conducted studies, reports, or similar analyses on the impact of social care provision on hospital admissions?
Date of Response: 24/03/2026
View Response: 11135.pdf
Freedom of Information Request Reference: 11115
Date Received: 02/02/2026
Summary:
Please provide the following information regarding substantive consultant medical and dental staff for your most recently completed job planning round (and in section 5, the past 5 years). Workforce Overview 1. The number of substantive consultants employed (headcount and WTE). 2. Your organisation’s current standard (or reference) job plan for a full-time consultant, including the normal DCC/SPA split. (Please provide the document or template if available). SPA Allocation 1. Number of consultant posts with SPA time and total SPAs allocated. 2. Typical SPA allocation in a 10-PA contract. 3. How many consultant posts have no SPA time allocated? 4. Count of consultants according to the number of SPAs stated in their job plan: a. <1.0 SPA b. 1.0–1.4 SPA c. 1.5–1.9 SPA d. 2.0–2.4 SPA e. ≥2.5 SPA 5. Since 1 April 2020, have there been any changes to SPA allocation policy or the standard consultant DCC/SPA split? Yes/No 6. If yes, please provide the any available documentation and briefly outline these changes. External Duties Royal Colleges, Specialist Associations and National Bodies Recently refreshed National guidance highlights the need to support professional and national roles within job planning. 1. Does your organisation have a policy or standard approach for recognising external professional duties such as: a. Roles for Royal Colleges / Faculties b. Specialist societies or associations c. National clinical networks, guideline groups or NHS national bodies 2. Regulatory roles (e.g., GMC, NICE) Please answer: Yes/No If yes, provide the policy or a summary. 3. For consultants who currently hold such external or national duties, please provide the number who: a. Have allocated PA(s) b. Are permitted to use existing SPA allocation c. Undertake these duties in their own time. SPA Delivery and Use 1. Does the organisation monitor whether planned SPA time is delivered? Yes/No 2. If yes, please provide a short description of the method. 3. Does the organisation have a policy or guidance on the protection of SPA time (e.g., discouraging routine cancellation or repurposing SPA for service pressures)? Yes/No 4. If yes, please provide the document. 5. Summary of activities SPA time was used for (e.g. education, CPD, audit, research, governance, external duties, etc). SPA Time Over the Past Five Years For each of the past five complete job-planning years, please provide an annual summary showing: 1. Number of consultants with SPA time 2. Total or average SPA time allocated (total SPA PAs or average per consultant). 3. Total or estimated SPA time used in that year.
Date of Response: 08/04/2026
View Response: 11115.pdf
Freedom of Information Request Reference: 10985
Date Received: 29/12/2025
Summary:
Please can you answer the following questions: Are midwives in your trust/board protected by Working Time Regulations 1998 (WTR)? Is there any system in place to audit or ensure compliance with WTR within your maternity service? Are midwives in your trust/board asked to opt out of WTR protections as a condition of employment? If so, is it made clear to staff that the opt-out is voluntary? Is the opt-out time-limited, or indefinite? And under what criteria, 'emergency' or otherwise, does your maternity service justify this opt-out? What are your staffing arrangements for covering on-call maternity services, either at home births and/or to cover short staffing within the maternity unit? How often are midwives in your trust/board called out to provide services overnight after working clinically during the day? In these instances, what is your system for compensatory rest and/or time off in lieu (TOIL)? If a midwife identifies that s/he is unable to provide safe care due to exhaustion, do you have a standard operating procedure for providing relief?
Date of Response: 25/03/2026
View Response: 10985.pdf
Freedom of Information Request Reference: 11080
Date Received: 26/01/2026
Summary:
1. From January 2025 to December 2025 how many people have attended A&E with mental health related issues. 2. Following attendance to A&E for mental health related issues how many were admitted to general/medical bed and/or mental health beds. 3. From January 2025 to December 2025 how many referrals has been made to the community mental health team. 4. From January 2025 to December 20245 how many of the referrals are put on the waiting list. 5. From January 2025 to December 2025 what is the longest wait on the waiting list for adult services and the community mental health team. 6. From January 2025 to December 2025 how many referrals to addictions services. 7. From January 2025 to December 2025 how many acute adults’ mental health bed is available within the area. 8. From January 2025 to December 2025 how many referrals has been made to all children and adolescents mental health services. 9. From January 2025 to December 2025 what is the longest wait time to been seen by children and adolescent mental health services. 10. From January 2025 to December 2025 How many of the referrals were rejected for child and adolescents’ mental health services. 11. From January 2025 to December 2025 how many referrals were made to neurodevelopment services. 12. From January 2025 to December 2025 what is the longest wait time to been seen by neurodevelopment services. 13. From January 2024 to December 2024 how many children and adolescents’ mental health beds are available within the area. 14. From January 2025 to December 2025 how many suicides review or Significant Adverse Event Review took place. 15. From January 2025 to December 2025 how many referrals were made to the DBI.
Date of Response: 24/03/2026
View Response: 11080.pdf
Freedom of Information Request Reference: 11183
Date Received: 16/02/2026
Summary:
1. For the calendar year of 2025, please could you tell me how many individual MRI examinations were performed overall? 2. For the calendar year of 2025, please could you give a breakdown of the individual MRI examinations performed into body part/area? For instance, how many brain scans, spine scans etc. I am happy with whichever body part description is input in the PACS system. 3. As of the start of 2026, what would the waiting time be (in weeks) for a routine MRI scan (for example how long would a patient have to wait if they were referred for a routine MRI scan of their knee)? 4. How much money was paid to private companies during the calendar year 2025 for the outsourcing of MRI either to mobile MRI units, private hospitals or private companies staffing hospital scanners to scan NHS patients? 5. From question 4 which companies were used and how many patients were scanned?
Date of Response: 16/03/2026
View Response: 11183.pdf
Freedom of Information Request Reference: 11182
Date Received: 16/02/2026
Summary:
Please provide all information for the most recent full financial year for which you hold complete data, unless otherwise stated. Spend, Suppliers & Contracting 1. Total spend on: o Interpreting o Translation o Transcription 2. Who is your current supplier(s) for language services? If multiple suppliers are used, please specify which services each supplier delivers. 3. Who is your provider for non spoken language services (e.g., BSL/ISL)? 4. Who is your provider for transcription services (if separate)? 5. Do you employ any in house interpreters or translators? 6. Contract expiry dates: o a) Without extensions o b) With all extensions applied 7. Name, phone number and email address of the contract manager for language services. 8. Name, phone number and email address of the person responsible for the language services budget. 9. Do you have any minimum durations set for interpreting bookings? If yes, please specify for each service type (spoken, non spoken, telephone, video). Activity Data – Latest Full Financial Year 10. Total number of: • Face to face interpreting assignments (spoken) + total hours • Face to face interpreting assignments (non spoken) + total hours • Telephone interpreting calls + total minutes • Video interpreting calls (spoken) + total minutes • Video interpreting calls (non spoken) + total minutes • Document translations + total words translated • Audio transcriptions + total audio duration 11. Top 20 highest volume languages for interpreting/translation. Performance, Fulfilment & Complaints 12. Fulfilment rate (%) for: • Face to face interpreting • Telephone interpreting • Video interpreting • Document translation • Audio transcription 13. Number of language service complaints received in the latest full financial year. 14. Percentage of positive vs negative feedback received regarding language services. 15. Languages your provider has been unable to source in the last 12 months. 16. Have any service credits been applied in the last 12 months? If yes, what performance issues were they linked to? Social Value, Tender Information & Pricing 17. Social value delivered under this contract in the last 12 months. 18. If tendered, please provide a copy of the winning bidder’s tender submission. 19. Contracted rates for: • Spoken face to face interpreting (hourly) • Non spoken face to face interpreting (hourly) • Telephone interpreting (per minute) • Spoken video interpreting (per minute) • Non spoken video interpreting (per minute) • Document translation (per word) • Audio transcription (per audio minute) 20. Has your provider increased their rates in the last 12 months? 21. What is the Authority’s typical route to market for procuring language services? Assistive Technology (BSL / Deaf Access) 22. Do you have a VRS (Video Relay Service) on demand service in place allowing Deaf BSL users to contact you via video when phoning? 23. Do you have a VRI (Video Remote Interpreting) on demand service in place for emergency/unplanned/immediate communication needs for Deaf patients or service users? If yes to either: • Who is the provider? • When was the service introduced? • Is it available 24/7? • Is there a cost to the Authority? Additional Data for the Most Recent Full Financial Year 24. Total number of spoken language requests. 25. Total number of non spoken language requests. 26. Total spend on spoken vs non spoken language services. 27. Fulfilment rates for spoken vs non spoken services. Final Clarification Request 28. If your provider offers additional provisions or specialist services (e.g., ISL, rare languages, emergency response, in person support, or other enhanced services), please provide details.
Date of Response: 18/03/2026
View Response: 11182.pdf
Freedom of Information Request Reference: 11180
Date Received: 13/02/2026
Summary:
1. Policy and pathways 1a. Does your Trust have a written policy, guideline, or clinical pathway addressing menopause symptoms in patients treated for breast cancer? o Yes / No o If yes, please provide the document or a web link. 1b. Is menopause care for breast cancer patients addressed within:     a) Breast cancer service guidelines     b) Oncology service guidelines     c) Menopause service guidelines     d) Not formally addressed ________________________________________ 2. Service provision 2a. Does your Trust provide specialist menopause support specifically for patients with a history of breast cancer? o Yes / No 2b. If yes, which of the following are available? (Please tick all that apply) o Dedicated menopause clinic o Joint oncology–gynaecology clinic o Breast cancer nurse–led service o Referral to general menopause clinic o External referral only ________________________________________ 3. Staffing and expertise 3a. Are any of the following routinely involved in menopause management for breast cancer patients? o Breast care nurses o Oncologists o Gynaecologists o GPs with special interest in menopause o Menopause specialist nurses o Sexual health specialist (including clinician/oncologist trained in sexual health and wellbeing) o Other, please specify......................... 3b. Does your Trust provide specific training or education on menopause management in breast cancer patients for clinical staff? o Yes / No ________________________________________ 4. Patient information and support Does your Trust provide written or digital patient information, other than publicly available information, specifically addressing menopause symptoms after breast cancer treatment? o Yes / No o If yes, please provide copies or links. ________________________________________ 5. Data collection and audit 5a. Does your Trust routinely collect or audit data on menopause symptoms or menopause-related quality of life in breast cancer patients? o Yes / No 5b. Has your Trust conducted any audit, service evaluation, or quality improvement project related to menopause care in breast cancer patients in the last 3 years? o Yes / No o If yes, please provide the title and date.
Date of Response: 13/03/2026
View Response: 11180.pdf
Freedom of Information Request Reference: 11179
Date Received: 17/02/2026
Summary:
Please provide the following information: 1. Any data held by your organisation regarding NHS-employed prescribing clinicians (including but not limited to medical practitioners, dentists, nurse independent prescribers, pharmacist prescribers and allied health professional prescribers) who have left NHS Scotland employment within the last five financial years. 2. Any recorded destination-of-leaver data indicating movement into: a. Private healthcare practice b. Independent clinical practice c. Cosmetic or aesthetic medicine services d. Non-surgical cosmetic treatment providers e. Self-employment in healthcare provision 3. Any internal workforce impact assessments, modelling, workforce planning assumptions, risk registers or reports produced since 2018 that reference: a. Workforce loss to the private healthcare sector b. Workforce loss to the cosmetic or aesthetic medicine sector c. Reduced NHS clinical capacity linked to private sector migration d. Prescribers reducing NHS contracted hours in order to undertake private aesthetic practice 4. Any estimates held regarding: a. Full-time equivalent (FTE) clinical capacity lost due to prescribers undertaking private practice b. Waiting list impact associated with workforce attrition to private practice c. Training investment loss associated with prescribers leaving NHS Scotland employment 5. Any correspondence, briefing papers, or policy discussions held since 2018 relating to: a. The migration of NHS clinicians into the cosmetic/aesthetic medicine sector b. The impact of dual practice (NHS and private aesthetics work) c. Retention risks linked to private sector injectable or cosmetic treatment markets 6. Any plans, current or proposed, to: a. Monitor workforce migration into cosmetic or aesthetic medicine b. Record private sector destination data more accurately c. Mitigate workforce displacement related to private aesthetic practice
Date of Response: 18/03/2026
View Response: 11179.pdf
Freedom of Information Request Reference: 11178
Date Received: 17/02/2026
Summary:
No. Question Response Format 1 Does your Trust/Health Board currently provide or commission a Prosthetic service? 2 Does your Trust/Health Board currently provide or commission an Orthotic service for patients? 3a If you answered Yes to Question 1: Is your Prosthetic service delivered in-house (i.e. directly employed NHS staff) or is it contracted out to an external provider? 3b If you answered Yes to Question 2: Is your Orthotic service delivered in-house (i.e. directly employed NHS staff) or is it contracted out to an external provider? 4 Does your Trust/Health Board carry out workforce planning analysis for your Allied Health Professional (AHP) workforce? 5a If you answered Yes to Question 4: Does your AHP workforce planning specifically include your Prosthetic service workforce (whether in-house or contracted)? 5b If you answered Yes to Question 4: Does your AHP workforce planning specifically include your Orthotic service workforce (whether in-house or contracted)? 6a If your Prosthetic service is contracted out (as indicated in Question 3a): Does your Trust/Health Board carry out workforce planning for the contracted Prosthetic service? 6b If your Orthotic service is contracted out (as indicated in Question 3b): Does your Trust/Health Board carry out workforce planning for the contracted Orthotic service? 7a If you answered Yes to Question 6a: How does your Trust/Health Board collate workforce planning data from the contracted Prosthetic service provider? Please describe the process, including the frequency of data collection and what data is gathered. 7b If you answered Yes to Question 6b: How does your Trust/Health Board collate workforce planning data from the contracted Orthotic service provider? Please describe the process, including the frequency of data collection and what data is gathered. 8 If your Trust/Health Board does not carry out workforce planning for its Prosthetic and/or Orthotic services (whether in-house or contracted), please explain what steps you are taking to secure the prosthetic and/orthotic workforce pipeline. 9 Does your Trust/Health Board include data from its Prosthetic and/or Orthotic services (whether in-house or contracted) in any workforce returns submitted to NHS England, NHS Wales, NHS Scotland, or equivalent national workforce planning bodies? 10 Please provide the current whole time equivalent (WTE) staffing establishment for your Prosthetic and/or Orthotic services, broken down by: (a) Prosthetists, (b) Orthotists, (c) Prosthetic/Orthotic Technicians, (d) Prosthetic/Orthotic support workers (e) Please indicate whether each figure relates to in-house or contracted staff.
Date of Response: 17/03/2026
View Response: 11178.pdf
Freedom of Information Request Reference: 11177
Date Received: 17/02/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Name of medicine 1.1 Abiraterone (Zytiga or generic abiraterone) 1.2 Apalutamide (Erleada) 1.3 Cabazitaxel (Jevtana or generic cabazitaxel) 1.4 Darolutamide (Nubeqa) 1.5 Enzalutamide (Xtandi) 1.6 Talazoparib (Talzenna) 1.7 Docetaxel 1.8 Relugolix (Orgovyx, Ryeqo) 1.9 Olaparib (Lynparza) Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Name of medicine 2.1 Docetaxel for prostate cancer 2.2 Olaparib (Lynparza) for prostate cancer 2.3 Talazoparib (Talzenna) for prostate cancer 2.4 Relugolix (Orgovyx) for prostate cancer Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Name of medicine 3.1 Abiraterone (Zytiga or generic abiraterone) 3.2 Apalutamide (Erleada) 3.3 Cabazitaxel (Jevtana or generic cabazitaxel) 3.4 Darolutamide (Nubeqa) 3.5 Enzalutamide (Xtandi) Q4. How many patients were treated with the following combinations in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle. Name of medicine 4.1 Darolutamide (Nubeqa) + Docetaxel 4.2 Darolutamide (Nubeqa) monotherapy 4.3 Olaparib (Lynparza) + Abiraterone Q5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Name of medicine 5.1 Abiraterone 5.2 Enzalutamide
Date of Response: 17/03/2026
View Response: 11177.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Mainpoint
102 Westport
Edinburgh
EH3 9DN

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS
NHS Lothian Charity Logo
Tel: +44 (0)131 465 5850
Email: loth.charity@nhs.scot

Scottish Registered Charity No: SC007342
The official charity of NHS Lothian.
From the everyday to the transformational, we support NHS Lothian to excel for all the communities it serves: patients, families, carers and staff.
Making healthcare better, together.
Find out more about NHS Lothian Charity
Donate